Dizal

Dizal (stock code: 688192) is an innovative biopharmaceutical company focused on the research, development, and commercialization of innovative therapies in the fields of malignant tumors and immunological diseases. The company adheres to the concept of original innovation in its R&D, aiming to launch first-in-class drugs and treatments with breakthrough potential to address unmet global clinical needs. Leveraging industry-leading translational science and new drug molecule design and screening technology platforms, the company has established a product pipeline with six globally competitive candidates. Two of its leading products are in global pivotal clinical trials, with one already approved for marketing.